The protective effect of a new oral anti-asthma agent (ketotifen, HC 20--511) against experimentally induced bronchospasm (5 different models).
D000109:Acetylcholine / Q000494:pharmacology; D000336:Aerosols; D000941:Antigens; D001241:Aspirin / Q000494:pharmacology; D001565:Benzoates / Q000494:pharmacology; D001986:Bronchial Spasm / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D004311:Double-Blind Method; D006632:Histamine / Q000494:pharmacology; D006634:Histamine H1 Antagonists / Q000627:therapeutic use*; D006801:Humans; D005082:Physical Exertion; D010880:Piperidines / Q000627:therapeutic use*; D010919:Placebos; D013645:Tartrazine / Q000494:pharmacology; D013876:Thiophenes / Q000627:therapeutic use*
D000336:Aerosols; D000941:Antigens; D001565:Benzoates; D006634:Histamine H1 Antagonists; D010880:Piperidines; D010919:Placebos; D013876:Thiophenes; D006632:Histamine; D013645:Tartrazine; D000109:Acetylcholine; D001241:Aspirin